Bio-Gene Technology Ltd Market Cap ($2.81 Million)
Market Cap & Net Worth: Bio-Gene Technology Ltd (BGT)
Bio-Gene Technology Ltd market cap. Bio-Gene Technology Ltd (AU:BGT) has a market capitalization of $2.81 Million (AU$3.97 Million) as of November 8, 2026. Listed on the AU stock exchange, this Australia-based company holds position #29550 globally and #1659 in its home market, demonstrating a -23.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bio-Gene Technology Ltd's stock price AU$0.01 by its total outstanding shares 305061108 (305.06 Million). Also see cash efficiency ratio of Bio-Gene Technology Ltd for how efficiently the company converts equity into cash flow.
Bio-Gene Technology Ltd Market Cap History (2017–2026)
Bio-Gene Technology Ltd market cap history from 2017 to 2026. Data shows change from $42.09 Million to $2.81 Million (-26.34% CAGR). Check current stock price of Bio-Gene Technology Ltd for real-time trading data and today's change.
Bio-Gene Technology Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bio-Gene Technology Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Bio-Gene Technology Ltd net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
11.68x
Bio-Gene Technology Ltd's market cap is 11.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $42.09 Million | $6.32K | -$1.05 Million | 6664.15x | N/A |
| 2018 | $21.59 Million | $344.45K | -$2.83 Million | 62.67x | N/A |
| 2019 | $43.17 Million | $508.76K | -$1.92 Million | 84.85x | N/A |
| 2020 | $30.22 Million | $907.58K | -$1.93 Million | 33.30x | N/A |
| 2021 | $44.25 Million | $62.61K | -$2.40 Million | 706.74x | N/A |
| 2022 | $21.59 Million | $445.73K | -$2.91 Million | 48.43x | N/A |
| 2023 | $12.95 Million | $149.23K | -$3.10 Million | 86.78x | N/A |
| 2024 | $9.28 Million | $18.32K | -$2.41 Million | 506.64x | N/A |
| 2025 | $4.96 Million | $425.07K | -$2.58 Million | 11.68x | N/A |
Competitor Companies of BGT by Market Capitalization
Companies near Bio-Gene Technology Ltd in the global market cap rankings as of November 8, 2026. Also see Bio-Gene Technology Ltd balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Bio-Gene Technology Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Bio-Gene Technology Ltd (2017–2026)
Market capitalization of Bio-Gene Technology Ltd from 2017 to today. Between 2017 and today, Bio-Gene Technology Ltd's market cap moved from $42.09 Million to $ 2.81 Million, with a yearly change of -26.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$2.81 Million | -43.48% |
| 2025 | AU$4.96 Million | -46.51% |
| 2024 | AU$9.28 Million | -28.33% |
| 2023 | AU$12.95 Million | -40.00% |
| 2022 | AU$21.59 Million | -51.22% |
| 2021 | AU$44.25 Million | +46.43% |
| 2020 | AU$30.22 Million | -30.00% |
| 2019 | AU$43.17 Million | +100.00% |
| 2018 | AU$21.59 Million | -48.72% |
| 2017 | AU$42.09 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Bio-Gene Technology Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.81 Million USD |
| MoneyControl | $2.81 Million USD |
| MarketWatch | $2.81 Million USD |
| marketcap.company | $2.81 Million USD |
| Reuters | $2.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bio-Gene Technology Ltd
Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with Jame… Read more